Deepinder Goyal-led healthtech startup Temple has acquired London-based Longevous, an evidence-based longevity medicine practice, as it looks to strengthen its clinical and scientific capabilities ahead of its launch.
The acquisition will bring Longevous founders Dr Robert Mohr and Dr Avi Roy, along with their team, into Temple full time, Goyal said in a post on X.
Dr Mohr will join Temple as Chief Medical Officer. A board-certified physician with nearly two decades of clinical experience, Mohr moved from emergency medicine to longevity medicine, with expertise spanning preventive and precision medicine.
Meanwhile, Roy will join Temple as Head of Science. An Oxford-trained biomedical scientist, Roy has worked at the intersection of longevity science and business. He is the co-founder of Founders Health and UDA and was previously a research fellow at the Centre for the Advancement of Sustainable Medical Innovation at the University of Oxford.
According to Goyal, the duo first met him at a dinner event in London a couple of months ago. Their conversation around longevity science eventually led them to try Temple themselves.
For the next two months, Mohr and Roy used Temple as their daily wearable and worked with its science team to evaluate its proprietary ‘Entropy’ metric and the data collected by the device. They also challenged some of the company’s assumptions and reviewed Temple’s first scientific manuscripts before submission.
“Given how personally invested they’d become, I asked if they’d consider building Temple with me full time,” Goyal said.
Longevous will continue to operate under Temple, with Mohr and Roy continuing to look after its existing clients.
Temple is Goyal’s healthtech venture focused on building wearable technology for tracking physiological signals and longevity-related metrics. The startup has been developing a wearable device that sits near the temple and has introduced a proprietary metric called Entropy, which it says measures the body’s real-time energy expenditure.
The company is expected to launch its wearable within the next year, with Goyal previously indicating that peer-reviewed studies would accompany its health claims.
Temple doubled its valuation to $375 million following a secondary share sale in July and launched its first employee stock ownership plan (ESOP) liquidity programme. The programme gives eligible employees an opportunity to sell a portion of their vested shares, providing liquidity ahead of a potential public listing or other future exit event.
